Literature DB >> 22556106

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Bevra H Hahn1, Maureen A McMahon, Alan Wilkinson, W Dean Wallace, David I Daikh, John D Fitzgerald, George A Karpouzas, Joan T Merrill, Daniel J Wallace, Jinoos Yazdany, Rosalind Ramsey-Goldman, Karandeep Singh, Mazdak Khalighi, Soo-In Choi, Maneesh Gogia, Suzanne Kafaja, Mohammad Kamgar, Christine Lau, William J Martin, Sefali Parikh, Justin Peng, Anjay Rastogi, Weiling Chen, Jennifer M Grossman.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22556106      PMCID： PMC3437757          DOI： 10.1002/acr.21664

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  71 in total

1.  Pharmacokinetics of mycophenolic acid in severe lupus nephritis.

Authors:  Paungpaga Lertdumrongluk; Poorichaya Somparn; Wonngarm Kittanamongkolchai; Opas Traitanon; Somratai Vadcharavivad; Yingyos Avihingsanon
Journal:  Kidney Int       Date:  2010-06-09       Impact factor: 10.612

Review 2.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jennifer M Grossman; Rebecca Gordon; Veena K Ranganath; Chad Deal; Liron Caplan; Weiling Chen; Jeffrey R Curtis; Daniel E Furst; Maureen McMahon; Nivedita M Patkar; Elizabeth Volkmann; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07-26       Impact factor: 4.794

3.  Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Authors:  Benjamin Terrier; Zahir Amoura; Philippe Ravaud; Eric Hachulla; Romain Jouenne; Bernard Combe; Christine Bonnet; Patrice Cacoub; Alain Cantagrel; Michel de Bandt; Olivier Fain; Bruno Fautrel; Philippe Gaudin; Bertrand Godeau; Jean-Robert Harlé; Arnaud Hot; Jean-Emmanuel Kahn; Olivier Lambotte; Claire Larroche; Jean Léone; Olivier Meyer; Béatrice Pallot-Prades; Edouard Pertuiset; Pierre Quartier; Thierry Schaerverbeke; Jean Sibilia; Alexandre Somogyi; Martin Soubrier; Eric Vignon; Brigitte Bader-Meunier; Xavier Mariette; Jacques-Eric Gottenberg
Journal:  Arthritis Rheum       Date:  2010-08

4.  Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.

Authors:  Thórunn Jónsdóttir; Iva Gunnarsson; Ana Filipa Mourão; Tim Y Lu; Ronald F van Vollenhoven; David Isenberg
Journal:  Rheumatology (Oxford)       Date:  2010-04-27       Impact factor: 7.580

5.  Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation.

Authors:  Jennifer Mersereau; Mary Anne Dooley
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

6.  The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus.

Authors:  Meng-Yu Weng; Chia-Tse Weng; Ming-Fei Liu
Journal:  Clin Rheumatol       Date:  2010-03-02       Impact factor: 2.980

7.  The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.

Authors:  Hyejung Jung; Raja Bobba; Jiandong Su; Zhaleh Shariati-Sarabi; Dafna D Gladman; Murray Urowitz; Wendy Lou; Paul R Fortin
Journal:  Arthritis Rheum       Date:  2010-03

8.  Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.

Authors:  Jai Radhakrishnan; Dimitrios-Anestis Moutzouris; Ellen M Ginzler; Neil Solomons; Ilias I Siempos; Gerald B Appel
Journal:  Kidney Int       Date:  2009-11-04       Impact factor: 10.612

9.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Authors:  F A Houssiau; C Vasconcelos; D D'Cruz; G D Sebastiani; E de Ramon Garrido; M G Danieli; D Abramovicz; D Blockmans; A Cauli; H Direskeneli; M Galeazzi; A Gül; Y Levy; P Petera; R Popovic; R Petrovic; R A Sinico; R Cattaneo; J Font; G Depresseux; J-P Cosyns; R Cervera
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

10.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01
View more
  349 in total

1.  IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus.

Authors:  Ming Zhao; Yin Zhou; Bochen Zhu; Mengjie Wan; Tingting Jiang; Qiqun Tan; Yan Liu; Juqing Jiang; Shuaihantian Luo; Yixin Tan; Haijing Wu; Paul Renauer; Maria Del Mar Ayala Gutiérrez; Maria Jesús Castillo Palma; Rafaela Ortega Castro; Concepción Fernández-Roldán; Enrique Raya; Raquel Faria; Claudia Carvalho; Marta E Alarcón-Riquelme; Zhongyuan Xiang; Jinwei Chen; Fen Li; Guanghui Ling; Hongjun Zhao; Xiangping Liao; Youkun Lin; Amr H Sawalha; Qianjin Lu
Journal:  Ann Rheum Dis       Date:  2016-01-19       Impact factor: 19.103

2.  Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden.

Authors:  T Reese; A L Dickson; M M Shuey; J S Gandelman; A Barnado; K A Barker; J E Neal; O A Khan; W D Dupont; C M Stein; C P Chung
Journal:  Lupus       Date:  2019-06-20       Impact factor: 2.911

3.  Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.

Authors:  Maria Pereira; Eyal Muscal; Karen Eldin; M John Hicks; Anna Carmela P Sagcal-Gironella; Marietta DeGuzman; Scott E Wenderfer
Journal:  Pediatr Nephrol       Date:  2017-07-17       Impact factor: 3.714

Review 4.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 5.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 6.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

7.  Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease.

Authors:  Daniel J Birmingham; Ganesh Shidham; Annalisa Perna; Derek M Fine; Michael Bissell; Roger Rodby; Giuseppi Remuzzi; Michele Petri; Paul Hebert; Brad H Rovin; Lee A Hebert
Journal:  Ann Rheum Dis       Date:  2013-10-03       Impact factor: 19.103

8.  Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.

Authors:  Candace H Feldman; Jamie Collins; Zhi Zhang; Chang Xu; S V Subramanian; Ichiro Kawachi; Daniel H Solomon; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-11       Impact factor: 4.794

9.  Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.

Authors:  Jing Wang; Yuan-Yuan Qi; Xue-Ping Chen; Li Ma; Li-Li Zhang; Yu Zhao; Mei Wang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

10.  Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.

Authors:  Ranjan Gupta; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2016-09-13       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.